Envista Swings to Q3 Loss Amid Rising Sales, Debt

Ticker: NVST · Form: 10-Q · Filed: 2025-10-30T00:00:00.000Z

Sentiment: mixed

Topics: Dental Technology, Medical Devices, Quarterly Earnings, Net Loss, Revenue Growth, Debt Management, Goodwill Impairment

TL;DR

**NVST's Q3 net loss is a red flag despite sales growth, but the nine-month recovery suggests underlying strength post-impairment.**

AI Summary

Envista Holdings Corp (NVST) reported a net loss of $30.3 million for the three months ended September 26, 2025, a significant decline from the net income of $8.2 million in the prior-year period. Despite this, sales increased to $669.9 million from $601.0 million year-over-year, representing an 11.5% growth. For the nine months ended September 26, 2025, the company posted a net income of $14.1 million, a substantial recovery from the $1,119.8 million net loss in the same period of 2024, which was heavily impacted by a $1,153.8 million goodwill and intangible asset impairment charge. Gross profit for the nine-month period rose to $1,076.1 million from $1,000.2 million. Cash and cash equivalents increased to $1,133.9 million as of September 26, 2025, up from $1,069.1 million at December 31, 2024. Long-term debt also increased to $1,445.4 million from $1,278.3 million, while short-term debt was eliminated from $116.0 million. The company's strategic outlook includes continued investment in its Specialty Products & Technologies and Equipment & Consumables segments, with goodwill increasing by $100.8 million due to foreign currency translation.

Why It Matters

Envista's Q3 net loss, despite revenue growth, signals potential margin pressures or increased operational costs that investors should scrutinize. The significant recovery in nine-month net income, primarily due to the absence of last year's massive impairment charge, provides a clearer picture of underlying profitability trends. For employees, continued investment in R&D ($81.9 million for nine months) suggests ongoing innovation and job stability in key areas. Customers can expect new products and improved services from the company's focus on technological advancements in dental solutions. In a competitive dental market, Envista's ability to grow sales by 11.5% year-over-year indicates strong market demand for its products, but the increased long-term debt could impact future financial flexibility.

Risk Assessment

Risk Level: medium — The company reported a net loss of $30.3 million for the three months ended September 26, 2025, compared to a net income of $8.2 million in the prior year, indicating a deterioration in short-term profitability. Additionally, long-term debt increased by $167.1 million, from $1,278.3 million at December 31, 2024, to $1,445.4 million at September 26, 2025, which could strain financial resources.

Analyst Insight

Investors should closely monitor Envista's upcoming earnings calls for management's explanation of the Q3 net loss and strategies to improve short-term profitability. While the nine-month recovery is positive, the increase in long-term debt warrants attention; investors should assess the company's debt repayment plans and interest coverage ratios.

Financial Highlights

debt To Equity
0.47
revenue
$1,968.9M
operating Margin
7.25%
total Assets
$5,642.5M
total Debt
$1,445.4M
net Income
$14.1M
eps
N/A
gross Margin
54.67%
cash Position
$1,133.9M
revenue Growth
+6.0%

Revenue Breakdown

SegmentRevenueGrowth
Specialty Products & TechnologiesN/AN/A
Equipment & ConsumablesN/AN/A

Key Numbers

Key Players & Entities

FAQ

What caused Envista Holdings Corp's net loss in Q3 2025?

Envista Holdings Corp reported a net loss of $30.3 million for the three months ended September 26, 2025, compared to a net income of $8.2 million in the prior-year period. This shift occurred despite an increase in sales to $669.9 million, suggesting that increased costs or other non-operating factors outweighed revenue growth.

How did Envista's nine-month financial performance compare to the previous year?

For the nine months ended September 26, 2025, Envista Holdings Corp reported a net income of $14.1 million. This is a significant improvement from the net loss of $1,119.8 million reported for the same period in 2024, which was primarily due to a substantial goodwill and intangible asset impairment charge of $1,153.8 million in 2024.

What are Envista Holdings Corp's current cash and debt levels?

As of September 26, 2025, Envista Holdings Corp had cash and cash equivalents of $1,133.9 million, an increase from $1,069.1 million at December 31, 2024. The company's long-term debt increased to $1,445.4 million from $1,278.3 million, while short-term debt was reduced to zero from $116.0 million.

What is Envista Holdings Corp's strategy for its business segments?

Envista Holdings Corp operates in two segments: Specialty Products & Technologies and Equipment & Consumables. The company continues to develop, manufacture, and market dental implant systems, orthodontic appliances, digital imaging systems, and other dental equipment and supplies, indicating a focus on innovation and market presence in both areas.

How has Envista Holdings Corp's goodwill changed?

Envista Holdings Corp's total goodwill increased to $2,362.7 million as of September 26, 2025, from $2,261.9 million at December 31, 2024. This $100.8 million increase was primarily attributed to foreign currency translation adjustments.

What new accounting standards might impact Envista Holdings Corp?

Envista Holdings Corp is evaluating the impact of several new FASB ASUs, including ASU 2025-07 on Derivatives and Hedging, ASU 2025-06 on Internal-Use Software, ASU 2024-04 on Debt with Conversion and Other Options, ASU 2024-03 on Expense Disaggregation Disclosures, and ASU 2023-09 on Income Tax Disclosures. These updates could affect future financial reporting.

What is Envista Holdings Corp's allowance for credit losses?

As of September 26, 2025, Envista Holdings Corp's allowance for credit losses was $21.8 million, down from $26.6 million at December 31, 2024. The company recorded a provision for credit losses of $6.0 million for the nine months ended September 26, 2025.

How much did Envista Holdings Corp spend on research and development?

For the nine months ended September 26, 2025, Envista Holdings Corp spent $81.9 million on research and development. This represents an increase from $72.4 million spent in the same period of 2024, indicating continued investment in innovation.

What is the total value of Envista Holdings Corp's inventories?

As of September 26, 2025, Envista Holdings Corp's net inventories totaled $290.8 million, an increase from $241.0 million at December 31, 2024. This includes finished goods of $216.8 million, work in process of $27.9 million, and raw materials of $100.1 million, offset by a reserve for obsolescence of $54.0 million.

What is the outlook for Envista Holdings Corp's profitability?

While Envista Holdings Corp experienced a net loss in Q3 2025, the significant recovery to a net income of $14.1 million for the nine-month period, compared to a large loss in the prior year, suggests an improving underlying profitability trend. Investors should monitor future reports for sustained positive net income and effective management of increased long-term debt.

Risk Factors

Industry Context

Envista Holdings operates in the dental and medical device industry, a sector characterized by innovation, regulatory oversight, and consolidation. Key trends include the shift towards digital dentistry, demand for minimally invasive procedures, and an aging global population driving demand for dental and orthopedic products. Competition is intense, with both large diversified players and specialized niche companies.

Regulatory Implications

As a medical device manufacturer, Envista is subject to stringent regulations from bodies like the FDA in the U.S. and similar agencies globally. Compliance with quality standards, product approvals, and post-market surveillance is critical. Changes in healthcare policy or reimbursement rates could also impact demand for its products.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Goodwill
An intangible asset that represents the excess of the purchase price of an acquired company over the fair value of its identifiable net assets. It reflects brand reputation, customer relationships, and other unidentifiable assets. (Envista has a significant goodwill balance ($2,362.7 million), which is subject to impairment testing and can lead to large write-downs if its value declines.)
Intangible Assets
Non-physical assets that have value, such as patents, trademarks, copyrights, and customer lists. Like goodwill, they are subject to impairment. (The company had $645.8 million in net intangible assets, and a significant impairment charge in the prior year indicates potential volatility.)
Accumulated Deficit
The cumulative net losses of a company that have not been offset by net income. It represents retained earnings that are negative. (Envista has an accumulated deficit of $473.3 million, indicating that historically, the company's losses have exceeded its profits.)
Operating Lease Right-of-Use Assets
Assets recognized under accounting standards for leases, representing the right to use an asset for the lease term. (These assets, totaling $148.0 million, are part of the company's long-term assets and are linked to operating lease liabilities.)
Treasury Stock
Stock that a company has repurchased from the open market. It is recorded at cost and reduces total stockholders' equity. (Envista's treasury stock increased significantly from $50.5 million to $199.0 million, indicating share buybacks or other repurchases.)

Year-Over-Year Comparison

Envista Holdings Corp. has shown a significant revenue increase of 11.5% in Q3 2025 to $669.9 million, compared to $601.0 million in Q3 2024. While the nine-month period shows a strong recovery in net income to $14.1 million from a substantial loss of $1,119.8 million (largely due to a $1,153.8 million goodwill impairment in the prior year), the most recent quarter (Q3 2025) reported a net loss of $30.3 million, a reversal from the $8.2 million net income in Q3 2024. Long-term debt has increased, while short-term debt has been eliminated, and cash reserves have grown.

Filing Stats: 4,683 words · 19 min read · ~16 pages · Grade level 8 · Accepted 2025-10-30 16:20:01

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION PAGE

Condensed Consolidated Balance Sheets

Item 1. Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Income (Loss) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 40

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 40

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 40

Other Information

Item 5. Other Information 40

Exhibits

Item 6. Exhibits 41

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ENVISTA HOLDINGS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) ($ in millions, except share amounts) As of September 26, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 1,133.9 $ 1,069.1 Trade accounts receivable, less allowance for credit losses of $ 21.8 and $ 26.6 , respectively 405.9 363.0 Inventories, net 290.8 241.0 Prepaid expenses and other current assets 117.7 115.2 Total current assets 1,948.3 1,788.3 Property, plant and equipment, net 288.4 277.0 Operating lease right-of-use assets 148.0 142.8 Other long-term assets 249.3 230.6 Goodwill, net 2,362.7 2,261.9 Other intangible assets, net 645.8 649.9 Total assets $ 5,642.5 $ 5,350.5 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ — $ 116.0 Trade accounts payable 156.0 174.6 Accrued expenses and other liabilities 626.5 553.6 Operating lease liabilities 39.2 34.5 Total current liabilities 821.7 878.7 Operating lease liabilities 117.5 118.9 Other long-term liabilities 169.7 139.8 Long-term debt 1,445.4 1,278.3 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.01 par value, 15.0 million shares authorized; no shares issued or outstanding at September 26, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value, 500.0 million shares authorized; 175.3 million shares issued and 165.0 million shares outstanding at September 26, 2025; 174.2 million shares issued and 172.2 million shares outstanding at December 31, 2024 1.8 1.7 Treasury stock at cost; 10.3 million shares and 2.0 million shares at September 26, 2025 and December 31, 2024, respectively ( 199.0 ) ( 50.5 ) Additional paid-in capital 3,871.8 3,842.1 Accumulated deficit ( 473.3 ) ( 487.4 ) Accumulated other comprehensive loss ( 113.1 ) ( 371.1 ) Total stockholders' equity 3,088.2 2,934.8 Total liabilities and stockholders' equity $ 5,642.5 $ 5,350.5 See the accompanying Notes to the Condensed Consolida

View on Read The Filing